The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute ly...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaufman GP, Ristow KM, Markovic SN, Porrata LF
Format: article
Language:EN
Published: Dove Medical Press 2014
Subjects:
Online Access:https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee
Tags: Add Tag
No Tags, Be the first to tag this record!